Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-046836
Filing Date
2024-11-19
Accepted
2024-11-19 16:35:54
Documents
60
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1182130
2 ex31-1.htm EX-31.1 17700
3 ex31-2.htm EX-31.2 17495
4 ex32-1.htm EX-32.1 12878
  Complete submission text file 0001493152-24-046836.txt   6225165

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE awh-20240930.xsd EX-101.SCH 46830
6 XBRL CALCULATION FILE awh-20240930_cal.xml EX-101.CAL 50145
7 XBRL DEFINITION FILE awh-20240930_def.xml EX-101.DEF 225423
8 XBRL LABEL FILE awh-20240930_lab.xml EX-101.LAB 417690
9 XBRL PRESENTATION FILE awh-20240930_pre.xml EX-101.PRE 319072
63 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 893326
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 241476746
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)